Holds one active US DMF and one valid CEP for fluoxetine, filing since 1999. Its 2025 FDA inspection closed as NAI, and its GMP is recognised in 15 markets.
Holds one active US DMF and one valid CEP for fluoxetine, filing since 1998. Its 2025 FDA inspection closed as NAI, and its GMP is recognised in 26 markets.
Holds one active US DMF and 2 valid CEPs for fluoxetine, filing since 2024. Its 2025 FDA inspection closed as VAI, and its GMP is recognised in 19 markets.
Holds one active US DMF and 2 valid CEPs for fluoxetine, filing since 2012. Its 2025 FDA inspection closed as VAI, and its GMP is recognised in 18 markets.
Holds one valid CEP for fluoxetine, filing since 2025. Its 2024 FDA inspection closed as VAI, and its GMP is recognised in 6 markets.
Holds 2 active US DMFs and one valid CEP for fluoxetine, filing since 2005. Its 2025 FDA inspection closed as VAI.
Holds one active US DMF for fluoxetine, filing since 2025. Its 2023 FDA inspection closed as NAI.
This page filters the worldwide Fluoxetine manufacturer list to companies based in India. The order is set by active filings weighted by regulator, inspection outcomes and their recency, breadth of GMP recognition, and evidence of real exports, less any open risk flags. Read the full method.
Tell us which markets you need to file in. These suppliers come back tiered for those markets, with the price corridor and an RFI sheet.
Start for free